Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.

Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, Betriu A, Binbrek AS, Califf R, Diaz R, Fanebust R, Fox K, Granger C, Heikkilä J, Husted S, Jansky P, Langer A, Lupi E, Maseri A, Meyer J, Mlczoch J, Mocceti D, Myburgh D, Oto A, Paolasso E, Pehrsson K, Seabra-Gomes R, Soares-Piegas L, Sùgrue D, Tendera M, Topol E, Toutouzas P, Vahanian A, Verheugt F, Wallentin L, White H.

Lancet. 1999 Aug 28;354(9180):716-22.

PMID:
10475182
2.
3.

One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.

Sinnaeve P, Alexander J, Belmans A, Bogaerts K, Langer A, Diaz R, Ardissino D, Vahanian A, Pehrsson K, Armstrong P, Van de Werf F; ASSENT-2 Investigators.

Am Heart J. 2003 Jul;146(1):27-32.

PMID:
12851604
4.
5.

Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.

Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, Ford I, Muir KW.

Lancet Neurol. 2015 Apr;14(4):368-76. doi: 10.1016/S1474-4422(15)70017-7. Epub 2015 Feb 26.

PMID:
25726502
6.

Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.

Tanswell P, Modi N, Combs D, Danays T.

Clin Pharmacokinet. 2002;41(15):1229-45. Review.

PMID:
12452736
7.

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.

Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators.

Lancet. 2001 Aug 25;358(9282):605-13.

PMID:
11530146
8.

A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction.

Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators.

N Engl J Med. 1997 Oct 16;337(16):1124-30.

9.

Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes.

Mehta RH, Alexander JH, Van de Werf F, Armstrong PW, Pieper KS, Garg J, Califf RM, Granger CB.

JAMA. 2005 Apr 13;293(14):1746-50.

PMID:
15827313
10.

TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.

Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, Grollier G, Giugliano RP, Frey M, Mueller HS, Steingart RM, Weaver WD, Van de Werf F, Braunwald E.

Circulation. 1998 Dec 22-29;98(25):2805-14.

11.

Patency trials with reteplase (r-PA): what do they tell us?

Bode C, Nordt TK, Peter K, Smalling RW, Runge MS, Kübler W.

Am J Cardiol. 1996 Dec 19;78(12A):16-9. Review.

PMID:
8990406
12.

Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).

Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FW, Armstrong PW, Krumholz HM, Van de Werf F, Danays T, Cheeks M, Granger CB; ASSENT-2 and ASSENT-3 Investigators.

Am J Cardiol. 2004 Aug 1;94(3):279-83.

PMID:
15276088
13.

Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction.

Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A.

Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. Review.

15.

Off-target effects of thrombolytic drugs: apolipoprotein A-I proteolysis by alteplase and tenecteplase.

Gomaraschi M, Ossoli A, Vitali C, Pozzi S, Vitali Serdoz L, Pitzorno C, Sinagra G, Franceschini G, Calabresi L.

Biochem Pharmacol. 2013 Feb 15;85(4):525-30. doi: 10.1016/j.bcp.2012.11.023. Epub 2012 Dec 5.

PMID:
23219857
17.

Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.

Szabo S, Letsch R, Ehlers R, Walter T, Kazmaier S, Helber U, Hoffmeister HM.

Thromb Res. 2002 Apr 15;106(2):113-9.

PMID:
12182909
18.

"Tenecteplase--the best among the equals.".

Saran RK, Sethi R, Nagori M.

Indian Heart J. 2009 Sep-Oct;61(5):454-8. Review.

PMID:
20635761
19.

A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.

Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O'Brien B, Bladin C, McElduff P, Allen C, Bateman G, Donnan G, Davis S, Levi C.

N Engl J Med. 2012 Mar 22;366(12):1099-107. doi: 10.1056/NEJMoa1109842.

20.

Supplemental Content

Support Center